Liz Pekas, PhD

The @TheLancetEndo Commission said: preclinical obesity = risk. Clinical obesity = active disease >> Treat each accordingly. Evidence-based, standard medicine. Not complicated. Now a @NatureComms study confirms preclinical obesity = risk; it does not show it is disease. Exactly the Commission’s position. Spinning this as “proof” that the Commission’s framework is confusing and dismissing a legitimate scientific debate held @ObesityCan as “unhelpful”—frankly makes little sense…unless the aim is to foment controversy, for whatever reason. That is what’s truly unhelpful

📢 New journal launch The first article in Diabetes, Obesity, and Cardiometabolic CARE has been published. 📝 "Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity" presents evidence-based guidance for medication use as part of comprehensive, person-centered obesity care. 🔗 Read more: doi.org/10.2337/doci25… #DOCMCARE #ObesityCare #StandardsOfCare

Our Delphi published Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement sciencedirect.com/science/articl… with @TinaVilsb et al

AHA/ACC have released the 2025 High Blood Pressure Guideline, emphasizing prevention and early treatment to reduce cardiovascular disease risk. Read the Guideline in @HyperAHA & @CircAHA and check out our hub with commentaries and more: ahajrnls.org/4mlSNs4...

Staying active = living longer Meta-analysis 85 studies: ✅ Consistent or increasing physical activity over adulthood linked to: 🔻20–40% lower all-cause mortality 🔻30–40% lower CVD mortality 🩺 Even PA below guidelines offered benefits bjsm.bmj.com/content/early/…

📊 Tirzepatide: Don’t stop at 12 weeks! Post-hoc analysis 🕒 Early vs Late Responders (Week 12) 🔹 Early: ≥5% weight loss → 82% 🔹 Late: <5% weight loss → 18% 📉 But by Week 72… ✅ 90% of late responders achieved ≥5% wt loss 📈 Most by ~25 weeks pubmed.ncbi.nlm.nih.gov/40677091/

💡Dr @ArunJSanyalVCU shares insights from the phase 3 ESSENCE trial examining #semaglutide 2.4 mg for metabolic dysfunction-associated #steatohepatitis. 📽️Watch here👉 ow.ly/Z6nY50WoxQL #MASH #CKM #CVRM #CardioX #CardioEd

The muscle–adipose–liver axis is critical, yet underrecognized, in #MASLD. Sarcopenic obesity affects ~50% with #MASLD and drives ⬆️ ASCVD and liver fibrosis. @ChannapragadaV and I argue it's time to standardize definitions and intervene early: link.springer.com/article/10.100…

🚨 New ADA Consensus Report: A multidisciplinary call to action on NAFLD and MAFLD in people with diabetes. Learn how early detection, screening, and team-based care can change outcomes. 📰 Read now: diabetesjournals.org/care/lookup/do… #Diabetes #NAFLD #MAFLD @AmDiabetesAssn @ADA_DiabetesPro @DiabetesCareADA

Study showing 98% of individuals identified as having obesity based on BMI have excess adiposity. jamanetwork.com/journals/jama/…

please do help Zara our PhD student with this study is you are able to Thank you

Compared to low-volume physical activity, high-volume physical activity is associated with a lower risk of all-cause mortality but similar risk for clinical CAD events. ahajournals.org/doi/epub/10.11…

Happy World Liver Day! The liver is often overlooked in diabetes care. New guidance from @AmDiabetesAssn is coming soon—stay tuned! #WorldLiverDay #LiverHealth #DiabetesCare

@KatyWala @AHAScience @AANmember WOO!

🎉 Help us congratulate Dr. Adam Rosen who was selected as the new director of the School of Health & Kinesiology after a national search!

For all those #coffee lovers Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day Have it am and pm - to be on the safe side 😊 academic.oup.com/eurheartj/arti… @mmamas1973

FINALLY back to (light) squatting and it feels so good 🙌 Last set 6x3 @ 205lb

Great to see post trial follow-up of a CVOT! EMPAKIDNEY Empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. @NEJM

Now data on metformin benefits and hearing loss! Metformin use is associated with a dose-dependent reduction in hearing loss risk and lower mortality in people with T2 diabetes! Metformin keep giving! dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

Intermittent fasting at any time of day is good for losing (some) weight but does not reduce visceral adipose tissue. nature.com/articles/s4159…